Early CYP3A5 Genotype-Based Adjustment of Tacrolimus Dosage Reduces Risk of De Novo Donor-Specific HLA Antibodies and Rejection among CYP3A5-Expressing Renal Transplant Patients

Background/Objectives: Our previous retrospective single-center cohort study found, at 3-year follow-up, a trend toward low tacrolimus trough levels and an increased risk of de novo donor-specific anti-HLA antibodies (DSAs) and of antibody-mediated rejection (ABMR) in CYP3A5-expressing patients. Det...

Description complète

Détails bibliographiques

Auteurs principaux:	Kristina Schönfelder, Birte Möhlendick, Ute Eisenberger, Andreas Kribben, Winfried Siffert, Falko M. Heinemann, Anja Gäckler, Benjamin Wilde, Justa Friebus-Kardash
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2024-10-01
Collection:	Diagnostics
Sujets:	<i>CYP3A5</i> polymorphism tacrolimus dosage tacrolimus trough levels anti-HLA antibodies DSAs renal transplant rejection
Accès en ligne:	https://www.mdpi.com/2075-4418/14/19/2202
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!